




RealRate

PHARMACEUTICAL 2025

ANI Pharmaceuticals INC
Rank 109 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 78% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 3.9% points above the market average of 215%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	527,684	Assets	1,283,697
Cost of Goods Sold	0	Liabilities	855,167
Intangible Assets	601,824	Expenses	610,102
Liabilities, Current	193,680	Revenues	614,376
Liabilities, Non-Current	314,889	Stockholders Equity	428,530
Other Assets	97,326	Net Income	-18,522
Other Compr. Net Income	-3,513	Comprehensive Net Income	-20,278
Other Expenses	315,885	BaseVar	1,694,826
Other Liabilities	346,598	ECR before LimitedLiability	85%
Other Net Income	-22,796	Economic Capital Ratio	219%
Other Revenues	614,376		
Property and Equipment	56,863		
Research and Development	44,581		
Selling, General and Administrative Expense	249,636		